Among patients with isolated systolic hypertension and frailty, antihypertensive therapy is associated with improved outcomes.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and ...

Scientists have identified a widely prescribed hypertension drug as a potential key to extending lifespan and slowing aging.

Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Doxazosin remains a commonly used antihypertensive medication, although its use has been tainted by recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Hypertension (high blood pressure) effects one in three adults and is the number one cause of stroke in Northern Ireland.

Research from the Centre for Healthy Brain Ageing (CHeBA) suggests that high blood pressure treatment should be part of ...